{"transactions":[{"id":678393,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":20713,"kind":"person","name":"Chi Jeffrey","position":1,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-21T23:48:57.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":44964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive."}],"balance_after":44964,"derivative":{"exercise_price":6.54,"expiration_date":"2036-08-14","underlying":"Common Stock","underlying_shares":44964},"source":{"system":"sec-edgar","filing":"0001193125-26-361489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526361489/ownership.xml","form_type":"4"}},{"id":1110969,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":20713,"kind":"person","name":"Chi Jeffrey","position":1,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:05:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":61017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option will vest on June 11, 2026, and 1/36th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive."}],"balance_after":61017,"derivative":{"exercise_price":11.29,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61017},"source":{"system":"sec-edgar","filing":"0000950170-25-086146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025086146/ownership.xml","form_type":"4"}},{"id":1258485,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":20713,"kind":"person","name":"Chi Jeffrey","position":1,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-02-19T21:57:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":1130135,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vickers Venture Co-investment LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vickers Venture Co-investment LLC (\"Vickers Co-investment\") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":133364},"source":{"system":"sec-edgar","filing":"0000950170-25-023311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025023311/ownership.xml","form_type":"4"}},{"id":1258484,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":20713,"kind":"person","name":"Chi Jeffrey","position":1,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T21:57:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":133364,"ownership":{"direct":false,"nature":"By Vickers Venture Co-investment LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vickers Venture Co-investment LLC (\"Vickers Co-investment\") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":133364,"source":{"system":"sec-edgar","filing":"0000950170-25-023311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025023311/ownership.xml","form_type":"4"}},{"id":2115724,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":83028,"kind":"organization","name":"Vickers Venture Fund VI Pte Ltd","position":1,"cik":"0001839162","reported_name":"Vickers Venture Fund VI Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":122360,"kind":"organization","name":"Vickers Venture Fund VI (Plan) Pte Ltd","position":2,"cik":"0001839160","reported_name":"Vickers Venture Fund VI (Plan) Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}},{"id":20713,"kind":"person","name":"Chi Jeffrey","position":3,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}},{"id":122361,"kind":"person","name":"Ho Chris","position":4,"cik":"0001838628","reported_name":"Ho Chris","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}}],"security":"Warrants","published_at":"2022-11-16T02:47:41.000Z","date":"2022-11-10","kind":"other","acquired":false,"shares":578160,"ownership":{"direct":false,"nature":"By Vickeres Venture Fund VI (Plan) Pte Ltd"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I"},{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company (\"New Scilex Warrants\") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. (\"Sorrento\") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i)\nVickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture\nFund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company (\"New Scilex Warrants\") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. (\"Sorrento\") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i)\nVickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture\nFund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants."}],"balance_after":99000,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":578160},"source":{"system":"sec-edgar","filing":"0001104659-22-119278","document":"tm2229408-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000110465922119278/tm2229408-1_4seq1.xml","form_type":"4"}},{"id":2115723,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":83028,"kind":"organization","name":"Vickers Venture Fund VI Pte Ltd","position":1,"cik":"0001839162","reported_name":"Vickers Venture Fund VI Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":122360,"kind":"organization","name":"Vickers Venture Fund VI (Plan) Pte Ltd","position":2,"cik":"0001839160","reported_name":"Vickers Venture Fund VI (Plan) Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}},{"id":20713,"kind":"person","name":"Chi Jeffrey","position":3,"cik":"0001839163","reported_name":"Chi Jeffrey","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}},{"id":122361,"kind":"person","name":"Ho Chris","position":4,"cik":"0001838628","reported_name":"Ho Chris","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See footnote (1)"}}],"security":"Warrants","published_at":"2022-11-16T02:47:41.000Z","date":"2022-11-10","kind":"other","acquired":false,"shares":5261840,"ownership":{"direct":false,"nature":"By Vickers Venture Fund VI Pte Ltd"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I"},{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company (\"New Scilex Warrants\") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. (\"Sorrento\") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i)\nVickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture\nFund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company (\"New Scilex Warrants\") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. (\"Sorrento\") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i)\nVickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture\nFund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants."}],"balance_after":901000,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":5261840},"source":{"system":"sec-edgar","filing":"0001104659-22-119278","document":"tm2229408-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000110465922119278/tm2229408-1_4seq1.xml","form_type":"4"}}]}